GlassScriptPhysician profile
Paul Samuel Hackett
NPI 1154332393
$1,044.74
in general payments reported to CMS, 2019-2025
13 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $180 · 2021: $82.97 · 2022: $59.55 · 2023: $33.31 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $134.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $617.29 | 2019-2023 | Da Vinci Surgical System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.61 | 2019-2020 | |
| Braintree Laboratories, INC. | $57.59 | 2020-2023 | Suflave |
| Boston Scientific Corporation | $43.89 | 2019-2025 | Enhance Transcarotid Peripheral Access Kit |
| Masimo Corporation | $35.35 | 2021 | |
| Kerecis Limited | $32.46 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Tela Bio, INC. | $27.68 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Exact Sciences Corporation | $27.29 | 2025 | The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $24.84 | 2022 | |
| Smith+Nephew, INC. | $23.99 | 2021 | |
| Trevena, INC. | $20.58 | 2022 | |
| Cook Medical LLC | $13.69 | 2019 | |
| Baudax Bio INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Hackett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.